Regulatory

EMA continues to familiarize industry with new clinical trial legislation.

‘Independence’ the priority for the longstanding European Organization for Research and Treatment of Cancer, Winette van der Graaf tells Applied Clinical Trials in interview.

Medical device user-fees agreement, Aduhelm approval and access among issues in crosshairs.

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

Stress the importance of clinical studies today—and urge for formal approach to managing the pandemic and addressing specific public health needs more sustainably.

Dual efforts focused on more inclusive research and more diverse enrollment in pre- and post-approval studies.

Transition likely with looming end to emergency use authorizations tied to COVID-19 pandemic.

Remote inspection and ICH guidelines among topics discussed at Veeva's most recent TMF Innovation Forum.

Program looks to establish framework for agency and purchasers to “objectively rate” manufacturing sites.

Alleviating sponsor and investigator concerns around sharing of remote-assessment data in accordance with GCP and GDPR standards.

Study evaluates the use of AI-supported medical coding module.

Several legislative initiatives on table that would extend agency’s reach

What to make of UK’s draft resolution set for review on the international stage.

IP claims under microscope amid arguments over R&D policy and investment.

Leaked draft gives glimpse into potential new research proposals as part of the EU’s Horizon program.

The US Congress approved a federal spending package that increases funding for a range of programs to advance health and medicine.

Organization says either reform European drug development rules—or lose out on global competition.

Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.

New proposals aim to create higher standards for trial regulation.

A review of submission formats for drug development.

New EU guidance now officially in effect.

High upfront patient costs limit access to low-income populations.

In a highly unusual decision for a therapy approved by FDA, CMS has taken action to limit prescribing and use of Biogen’s new and controversial Alzheimer’s treatment Aduhelm.

Investigational medicinal products, trial sponsors, and registration all impacted by UK exit.

Survey uncovers pediatric-patient perspectives on plain language summaries.